CAR-T therapies represent a significant clinical advance for patients with certain types of advanced lymphoma. In clinical testing, Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) induced...
SAN FRANCISCO — Developing new medicines isn't a resource-efficient endeavor.
Estimates vary, but most molecules selected to begin clinical development won't end up on pharmacy shelves...
While Bristol-Myers executives successfully beat back Starboard and Wellington's efforts to derail the deal, the questions raised by that opposition remain.
By buying Celgene, Bristol-Myers...
Roche's $4.8 billion takeout of gene therapy specialist Spark Therapeutics looked like a typical biopharma transaction — that is, until the Federal Trade Commission...
MacroGenics stock took a beating Tuesday, dropping far more than any other biotech on the iShares NASDAQ Biotechnology Index as the ASCO conference closed....
Investors reacted negatively to the pushed-back readouts, sending shares of the Singapore-based biotech down nearly 20% between Tuesday's market close and Wednesday's.
Wall Street analysts,...
Array's combination of Braftovi (encorafenib) and Mektovi (binimetinib) already appears well received in the small clinical setting of advanced melanoma with BRAF V600E or...
The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation focused...
Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments like...
